Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immunogen Inc (NQ: IMGN ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open - Bid (Size) 31.23 (2,500) Ask (Size) 31.25 (400) Prev. Close 31.25 Today's Range N/A - N/A 52wk Range 12.43 - 31.24 Shares Outstanding 266,264,274 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024 March 09, 2024 Dive into the world of three unstoppable mega-cap stocks leading the charge amidst the bullishness in the market. Via InvestorPlace Amicus Therapeutics Stock Sees Improved Relative Strength Rating February 09, 2024 In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday. Via Investor's Business Daily Performance More News Read More ImmunoGen Inc. (NASDAQ: IMGN) Near Top of Volume Charts in Thursday Trading February 08, 2024 Via Investor Brand Network 3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List February 06, 2024 Via InvestorPlace 7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024 February 06, 2024 Via InvestorPlace Madrigal Pharmaceuticals Stock Shows Rising Relative Strength February 06, 2024 Via Investor's Business Daily AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall February 02, 2024 Via Benzinga ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 01, 2024 From ImmunoGen, Inc. Via Business Wire Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate January 29, 2024 Via Get News Exposures Product Safety AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures January 29, 2024 Via Benzinga Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate January 29, 2024 Via News Direct Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate January 29, 2024 Via TheNewswire.com Exposures Product Safety ABBV: This Top Biotech Just Went On A Buying Spree January 25, 2024 Via Talk Markets Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating January 23, 2024 Via Investor's Business Daily 7 Dividend Aristocrats That Will Pay You for Years to Come January 22, 2024 Via InvestorPlace Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83 January 18, 2024 Via Investor's Business Daily Cassava Sciences Stock Continues Showing Rising Relative Strength January 16, 2024 Via Investor's Business Daily Cramer Says This Major Healthcare Stock Is 'Ridiculously Cheap And Doing So Many Great Things' January 08, 2024 Via Benzinga Is AbbVie Stock a Buy Now? January 07, 2024 Via The Motley Fool Topics Intellectual Property Exposures Intellectual Property Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 January 05, 2024 Via Investor's Business Daily ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 03, 2024 From ImmunoGen, Inc. Via Business Wire 3 Biotech Stocks Set for Breakthroughs in 2024 January 02, 2024 Via InvestorPlace 10 Health Care Stocks Whale Activity In Today's Session January 02, 2024 Via Benzinga Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals December 29, 2023 Via MarketBeat Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 December 29, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.